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AbstrAct 
Objectives
To evaluate the association between experience in the 
management of acute pulmonary embolism, reflected 
by hospital case volume, and mortality.
Design
Multinational population based cohort study 
using data from the Registro Informatizado de la 
Enfermedad TromboEmbólica (RIETE) registry between 
1 January 2001 and 31 August 2018.
setting
353 hospitals in 16 countries.
ParticiPants
39 257 consecutive patients with confirmed diagnosis 
of acute symptomatic pulmonary embolism.
Main OutcOMe Measure
Pulmonary embolism related mortality within 30 days 
after diagnosis of the condition.
results
Patients with acute symptomatic pulmonary 
embolism admitted to high volume hospitals (>40 
pulmonary embolisms per year) had a higher burden 
of comorbidities. A significant inverse association was 
seen between annual hospital volume and pulmonary 
embolism related mortality. Admission to hospitals in 
the highest quarter (that is, >40 pulmonary embolisms 
per year) was associated with a 44% reduction in 
the adjusted odds of pulmonary embolism related 
mortality at 30 days compared with admission to 
hospitals in the lowest quarter (<15 pulmonary 
embolisms per year; adjusted risk 1.3% v 2.3%; 
adjusted odds ratio 0.56 (95% confidence interval 
0.33 to 0.95); P=0.03). Results were consistent in 
all sensitivity analyses. All cause mortality at 30 
days was not significantly reduced between the two 
quarters (adjusted odds ratio 0.78 (0.50 to 1.22); 
P=0.28). Survivors showed little change in the odds of 
recurrent venous thromboembolism (odds ratio 0.76 
(0.49 to 1.19)) or major bleeding (1.07 (0.77 to 1.47)) 
between the low and high volume hospitals.
cOnclusiOns
In patients with acute symptomatic pulmonary 
embolism, admission to high volume hospitals 
was associated with significant reductions in 
adjusted pulmonary embolism related mortality at 
30 days. These findings could have implications for 
management strategies.
Introduction
Pulmonary embolism remains a worldwide major 
health problem.1 It is among the most common causes 
of vascular death after myocardial infarction and 
stroke, and is the leading preventable cause of death in 
patients in hospital.2 The number of patients treated in 
a hospital is a well established determinant of outcomes 
after different medical and surgical conditions.3-5 For 
acute symptomatic pulmonary embolism, however, 
the contribution of experience to survival is less well 
understood.6 Treatment of pulmonary embolism is 
complex and requires considerable clinical skills. 
Patients with pulmonary embolism can present with 
a wide variety of clinical manifestations and could 
develop several complications that require timely 
recognition and treatment. The optimal treatment 
for patients with pulmonary embolism has markedly 
evolved over the past decade.7-10 Thus, there is a 
clinical priority to determine whether patients admitted 
to hospitals that only occasionally treat patients 
with pulmonary embolism have similar outcomes to 
those admitted to hospitals that treat patients with 
pulmonary embolism more frequently.
The Registro Informatizado de la Enfermedad 
TromboEmbólica (RIETE) Registry is an ongoing, 
multicentre, international, prospective registry of 
consecutive patients with symptomatic, objectively 
confirmed, acute venous thromboembolism.11-13 We 
hypothesised that experience in the management 
of acute pulmonary embolism, reflected by hospital 
case volume, would be significantly associated with a 
reduction in pulmonary embolism related mortality at 
30 days, after adjustment for differences in the patient 
case mix and hospital status (university based or not).
Methods
study design
For this study, we used the data from the RIETE 
registry, which prospectively collects information on 
patients with confirmed acute venous thromboembo-
lism (ClinicalTrials.gov NCT02832245). All patients 
provided written or oral consent for participation in 
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WhAt Is AlreAdy knoWn on thIs topIc
The number of patients treated in a hospital is a well established determinant of 
outcomes after different surgical conditions
However, the contribution of experience to survival after acute pulmonary 
embolism is less well understood
WhAt thIs study Adds
In patients with acute symptomatic pulmonary embolism, annual hospital 
volume had a significantly inverse association with mortality related to 
pulmonary embolism
Admission to lower volume hospitals was associated with significantly increased 
odds of adjusted mortality related to pulmonary embolism at 30 days
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the registry in accordance with local ethics committee 
requirements. Previous publications have described 
the design and conduct of the RIETE registry.14 15 
Briefly, at each participating RIETE site, investigators 
enrolled consecutive patients with acute venous 
thromboembolism. To ensure the reliability of coding 
and data entry, trained monitors periodically visited 
each participating hospital and compared the 
information in a random sample of hospital charts 
with the information entered into the RIETE database. 
RIETE also uses electronic data monitoring to prevent 
inconsistent or implausible values. In fact, previous 
studies have shown that data from RIETE closely 
represents that of multicentre administrative data, 
further supporting the representativeness and the 
validity of the data elements.16
Patient selection
Confirmatory testing for pulmonary embolism 
consisted of high probability ventilation-perfusion 
scintigraphy17; positive computed tomography (CT) 
pulmonary angiography for pulmonary embolism18; or 
venous compression ultrasonography of the lower limb 
that was positive for proximal deep vein thrombosis 
(DVT) in a patient presenting with chest symptoms.19 
This study included patients who were enrolled in 
the RIETE registry and had a diagnosis of acute, 
symptomatic pulmonary embolism from 1 January 
2001 to 31 August 2018.
Hospital volume
We defined hospital volume as the mean number of 
patients with pulmonary embolism per year admitted 
to each hospital during its participation in the RIETE 
registry. Accurate case ascertainment is essential for 
clinical registries to be valid and representative. We 
assessed case ascertainment in the RIETE registry 
by linking 16 random Spanish registry hospitals 
(four per hospital volume quarter) to the Spanish 
National Patient Registry during 2017 (see methods 
section in the supplementary appendix). Firstly, we 
used volume as a continuous variable to examine 
the association between hospital volume and the 
outcomes. We then categorised the volume of patients 
into volume quarters, with the lowest volume quarter 
(<15 patients/year) as the reference category. We chose 
volume quarters of patients to ensure a minimum 
number of hospitals in each volume category and 
to protect hospital identity. We also estimated the 
volume threshold above which an increase in volume 
was not associated with a reduction in the odds of an 
adverse outcome, by determining the change in the 
adjusted odds ratio associated with an increase in the 
pulmonary embolism volume by 10 cases. We defined 
the volume threshold as the annual hospital volume 
for which the relative change in the adjusted odds of 
the outcome associated with an increase of 10 patients 
with acute pulmonary embolism would be less than 
0.01 (that is, an odds ratio more than 0.99). To 
characterise the variation of the estimated threshold, 
we used bootstrapping techniques and replicated 
this analysis in 500 bootstrap samples to obtain 95% 
confidence intervals for the volume threshold.
study outcomes
The primary outcome was mortality related to 
pulmonary embolism at 30 days after diagnosis 
of the condition. The secondary outcome was all 
cause mortality at 30 days. We also examined the 
rates of death (all cause and related to pulmonary 
embolism) within seven days following the diagnosis 
of pulmonary embolism. The RIETE investigators 
used medical record review to assess vital status. 
For patients who died, further medical record review 
(and proxy interviews when necessary) assisted with 
determining the date and cause of death. For deaths 
confirmed by autopsy or those following a clinically 
severe pulmonary embolism (either initially or shortly 
after an objectively confirmed recurrent event), in the 
absence of any alternative diagnosis, the investigators 
were instructed to judge death as due to fatal 
pulmonary embolism. We also examined the rates of 
non-fatal recurrence of venous thromboembolism, and 
non-fatal bleeding events within 30 days following 
the diagnosis of pulmonary embolism (see methods 
section in the supplementary appendix).
statistical analysis
Because the proportions of missing data (for 
covariates) were below 5%, we assumed that the 
missing data were unlikely to drive the results of our 
study and as such, we analysed the observed data 
(complete case analysis). We performed χ2 tests for 
categorical variables and analyses of variance for 
continuous variables to compare the demographic and 
clinical characteristics of patients across the quarters 
of hospital volume. We reported the use of reperfusion 
treatments for pulmonary embolism, and appropriate 
treatment in patients admitted to each quarter of 
hospitals.
To assess the relation between hospital volume and 
the outcomes of interest, we constructed hierarchical 
multivariable logistic regression models for the overall 
cohort. To address potential confounding due to case 
mix variation, we controlled for the severity of illness 
and additional variables related to the outcome of 
patients with acute pulmonary embolism. The following 
models were generated sequentially to determine the 
successive influence of potential confounders on the 
relation between hospital volume and mortality:
•	 Unadjusted
•	 Adjusted only for age and sex
•	 Adjusted for age, sex, and the following covariates: 
coexisting conditions (cancer, immobilisation, 
chronic lung disease, chronic heart disease), 
severity of pulmonary embolism (heart rate, 
systolic blood pressure), and laboratory results 
(creatinine levels, haemoglobin levels) at hospital 
admission
•	 Adjusted for age, sex, cancer, immobilisation, 
chronic lung disease, chronic heart disease, 
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heart rate, systolic blood pressure, simplified 
pulmonary embolism severity index (sPESI),20 
creatinine levels, and haemoglobin levels 
(predefined main analysis) 
•	 Adjusted for age, sex, cancer, immobilisation, 
chronic lung disease, chronic heart disease, heart 
rate, systolic blood pressure, sPESI, creatinine 
levels, haemoglobin levels, and hospital status 
(university based or not).
All these models were built at the patient level, 
with hospital volume as a predictor variable with four 
categories. In all models, we accounted for clustering 
of patients within hospitals and hospitals clustered 
within countries. Interaction terms for year of 
diagnosis were included initially in the hospital level 
model, with a prespecified plan to remove this variable 
if no interaction was found.
We performed several sensitivity analyses. These 
analyses comprised the exclusion of outlier hospitals 
(those with too few or too many patients), exclusion 
of patients younger than 50 years old, exclusion of 
haemodynamically unstable patients, and exclusion 
of patients who received reperfusion treatments. 
Additional analyses included a falsification hypothesis 
analysis in which the cohort was evaluated for death 
related to cancer, chronic heart disease, and infection 
at 90 days. We also did alternative event rate estimation 
using inverse probability weighted regression adjust-
ment (supplementary appendix). All analyses were 
conducted with Stata version 13.1 (Stata, College 
Station, TX, USA). All hypothesis tests were two sided, 
with a significance level of 0.05.
Patient and public involvement
Patients were not involved in the design of this study, the 
choice of the outcome measures, or analysis of the data 
or dissemination. The study results will be available to 
patients, health professionals, and experts in the specialty 
through various channels: written communication, 
events and conferences, networks, social media, and 
patient-practitioner websites (including https://trombo.
info/about-us/?lang=en, where some RIETE investigators 
share data with practitioners and patients).
results
The study included 39 257 patients with pulmonary 
embolism from 353 hospitals in 16 countries (fig 
1). The linked data showed that the RIETE registry 
captured about 84% of the patients (n=602/718) with 
a final diagnosis of pulmonary embolism from each 
hospital, with little variation according to hospital 
volume (table S1, supplemental appendix). Annual 
hospital volume ranged from one to 112 admitted 
patients with pulmonary embolism per year (median 7; 
interquartile range 4-16). The final cohort was divided 
into four quarters of hospital volume, roughly equally 
sized, with about 10 000 patients in each quarter. 
Patients admitted to higher volume hospitals and 
those admitted to lower volume hospitals differed in 
pre-existing medical conditions, and relevant clinical, 
physiological, and laboratory parameters. Patients 
admitted to higher volume hospitals were older, had 
more comorbid diseases (cancer, chronic lung disease, 
congestive heart failure, and recent bleeding), and 
more signs of clinical severity (high risk according to 
sPESI, tachycardia, hypoxaemia, and hypotension) 
than those admitted to lower volume hospitals 
(table 1). Regarding in-hospital reperfusion treat-
ments, patients at low volume centres were more likely 
to receive reperfusion treatments (mostly systemic 
thrombolysis; 3.9% v 3.0%, P<0.001) and less likely 
to receive an inferior vena cava filter (2.7% v 3.3%, 
P=0.006). Compared with those admitted to high 
volume hospitals, patients at low volume centres 
were more likely to receive management that did not 
adhere to clinical practice guidelines (17.6% (n=1512) 
v 14.2% (n=1821), P<0.001; table S2, supplemental 
appendix).
The study had complete information on the 
primary outcome for all patients at the end of the 
30 day follow-up. At 30 days, the entire cohort had 
an all cause mortality rate of 5.4% (2139 of 39 257 
patients), and pulmonary embolism related mortality 
rate of 1.7% (668 of 39 257 patients; table 2). When 
examined as a completely continuous variable 
(between 1 and 112), hospital volume was associated 
with a significant reduction in the adjusted odds of 
pulmonary embolism related mortality rates at 30 days 
(P=0.04 for linear trend; fig 2). We saw no significant 
interaction between the volume-mortality relation and 
the year of pulmonary embolism diagnosis (P=0.99 
for interaction). There was not a specific volume 
threshold above which an increase in volume was not 
associated with a reduction in the odds of an adverse 
outcome. Compared with patients in the lowest quarter 
of hospital volume (quarter 1), patients in quarters 
2, 3, and 4 had a reduction in the adjusted odds of 
pulmonary embolism related death at 30 days of 
34% (P=0.06), 39% (P=0.05), and 44% (P=0.03), 
respectively (table 3 and table S3). The adjusted risk 
of pulmonary embolism related death at 30 days 
was 2.3% for patients in the lowest volume quarter 
and 1.3% for patients in the highest volume quarter 
(table 3).
Adjusted all cause mortality at 30 days was 5.2% 
for patients admitted to hospitals in the highest 
quarter and 6.4% for patients admitted to hospitals 
in the lowest quarter (table 3; odds ratio 0.78, 95% 
confidence interval 0.50 to 1.22; P=0.28). Similar 
findings were observed for all cause mortality and 
pulmonary embolism related mortality at seven 
days. At seven days, the adjusted risk of pulmonary 
embolism related death was 1.7% for patients in 
the lowest quarter of hospital volume and 1.0% for 
patients in the highest quarter, and the adjusted risk 
of all cause mortality was 2.7% for patients in the 
lowest quarter and 2.1% for patients in the highest 
quarter (table 3). Among survivors, we saw no clear 
association between hospital volume and non-fatal 
recurrence or major bleeding. Compared with the 
lowest quarter of hospital volume, higher volume was 
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not associated with a significant reduction in non-fatal 
recurrent venous thromboembolism in quarters 2, 3, 
and 4 (odds ratio 0.82 (95% confidence interval 0.54 
to 1.23), 0.74 (0.48 to 1.14), and 0.76 (0.49 to 1.19), 
respectively). We saw no significant difference in the 
incidence of non-fatal major bleeding events among 
hospital volume quarters (table 3).
To explore the sensitivity of our findings, we repeated 
the analysis with varying assumptions about the 
patient population and hospitals (table 4). Our results 
were not affected by the exclusion of younger patients 
(that is, age <50), haemodynamically unstable patients 
(that is, systolic blood pressure <90 mm Hg), patients 
who received reperfusion treatments, or exclusion of 
outlier hospitals.
We performed a falsification hypothesis analysis 
using the outcome of mortality related to cancer, 
chronic heart disease, and infection at 90 days. 
Compared with patients in the lowest quarter of 
hospital volume (quarter 1), patients in quarters 2, 
3, and 4 did not have a significant reduction in the 
adjusted odds of death at 90 days related to cancer 
(odds ratio 1.52 (95% confidence interval 1.06 to 
2.19), 1.57 (1.05 to 2.33), and 1.52 (1.00 to 2.31), 
respectively), chronic heart disease (1.25 (0.65 to 
2.40), 1.05 (0.52 to 2.09), and 0.86 (0.42 to 1.73), 
respectively), and infection (1.06 (0.61 to 1.82), 0.86 
(0.48 to 1.55), and 1.34 (0.74 to 2.44), respectively; 
table S4, supplementary appendix). The propensity 
score analysis confirmed reduced mortality related 
to pulmonary embolism for patients admitted to high 
volume hospitals, thereby supporting the primary 
results (table S5, supplementary appendix).
discussion
Principal findings
These data show an association between an increase 
in hospital volume of patients with pulmonary 
table 1 | baseline characteristics in patients with acute pulmonary embolism by hospital volume quarter (Q)
Hospital volume
Q1 (<15 patients/year) Q2 (15-25 patients/year) Q3 (>25-40 patients/year) Q4 (>40 patients/year)
Hospital characteristics
No of hospitals 253 52 28 20
No of beds (mean (SD)) 520 (428) 605 (361) 831 (516) 861 (342)
Teaching hospitals 88 (35) 16 (31) 18 (64) 13 (65)
Patient characteristics
Patients 8596 8130 9750 12 781
Age (mean (SD)) 65.6 (17.6) 67.2 (16.9) 68.0 (16.4) 67.7 (16.7)
Age >80 2024 (23.5) 2160 (26.6) 2670 (27.4) 3440 (26.9)
Male sex 4050 (47.1) 3756 (46.2) 4593 (47.1) 5968 (46.7)
Weight (kg; mean (SD)) 76.5 (16.0) 75.9 (16.3) 76.8 (16.2) 75.4 (16.4)
History of VTE 5069 (61.9) 5339 (67.8) 6488 (68.4) 8931 (71.1)
Cancer* 1751 (20.4) 1861 (22.9) 1875 (19.2) 3287 (25.7)
Recent surgery† 1010 (11.7) 898 (11.0) 1186 (12.2) 1504 (11.8)
Immobilisation for ≥4 days‡ 2038 (23.7) 1894 (23.3) 2040 (20.9) 2852 (22.3)
Chronic lung disease 1162 (13.5) 1142 (14.0) 1340 (13.7) 1918 (15.0)
Chronic heart disease 705 (8.2) 718 (8.8) 808 (8.3) 1293 (10.1)
Recent major bleeding 209 (2.4) 196 (2.4) 188 (1.9) 349 (2.7)
Pulse (beats; mean (SD)) 93.0 (19.7) 91.9 (20.0) 91.8 (20.0) 93.5 (20.2)
Pulse ≥110 beats/min 1744 (21.4) 1492 (19.5) 1903 (19.7) 2819 (22.3)
Systolic blood pressure (mm Hg; mean (SD)) 128.3 (23.7) 130.6 (23.1) 130.3 (24.3) 128.6 (24.5)
Systolic blood pressure <100 mm Hg 651 (7.6) 537 (6.6) 724 (7.4) 1217 (9.5)
Arterial oxyhaemoglobin saturation <90% 1971 (38.5) 1639 (33.9) 1947 (32.3) 3015 (38.4)
sPESI20
 Low risk 2755 (32.0) 2502 (30.8) 3193 (32.7) 3586 (28.1)
 High risk 5841 (68.0) 5628 (69.2) 6557 (67.3) 9195 (71.9)
Abnormal creatinine levels (>176.8 µmol/L) 1505 (18.2) 1542 (20.1) 1971 (20.6) 2381 (18.9)
Haemoglobin (g/L; mean (SD)) 130 (21) 130 (21) 131 (20) 130 (20)
Inappropriate management§ 1512 (17.6) 1251 (15.4) 1453 (14.9) 1821 (14.2)
Reperfusion treatment 334 (3.9) 206 (2.5) 326 (3.3) 383 (3.0)
IVC filter insertion 230 (2.7) 224 (2.8) 255 (2.6) 423 (3.3)
Data are number (%) of patients unless stated otherwise. SD=standard deviation; VTE=venous thromboembolism; sPESI=simplified pulmonary embolism severity index; IVC=inferior vena cava.
*Active or under treatment in previous year.
†In previous month.
‡Immobilised patients defined as non-surgical patients who had been immobilised (that is, total bed rest with bathroom privileges) for at least four days in the month before diagnosis of 
pulmonary embolism.
§Definition of inappropriate management provided in the supplemental appendix.
Patients with acute venous thromboembolism were enrolled in
Registro Informatizado de la Enfermedad TromboEmbólica registry
Excluded without symptomatic pulmonary embolism
Had deep vein thrombosis without symptomatic
  pulmonary embolism
Had asymptomatic pulmonary embolism
36 127
1643




Fig 1 | strObe study cohort flow diagram
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embolism and a lower risk adjusted mortality related 
to pulmonary embolism at 30 days. We observed a 
consistent dose-response relation between hospital 
volume and pulmonary embolism related mortality. 
The results were consistent with use of various 
adjustment techniques, across major subgroups of 
the patient populations and modelling assumptions, 
and were less likely to be driven by unmeasured 
confounding, represented by the lack of association 
between hospital volume of patients with pulmonary 
embolism and the falsification endpoints.
comparison with other studies
Few studies have investigated whether hospitals that 
care for large numbers of patients with pulmonary 
embolism have a lower short term mortality than those 
caring for low numbers of such patients.6 In a study 
of 10 354 patients admitted to hospital for pulmonary 
embolism based on administrative data from 186 
Pennsylvania hospitals, Aujesky and colleagues found 
that the hospitals with higher annual volumes (≥42 
patients/year) of patients with pulmonary embolism 
had significantly lower in-hospital and all cause 
mortality at 30 days than the hospitals with very low 
volumes (<10 patients/year). Our study’s large sample 
size, availability of good quality clinical data that 
allowed for adjustment for potential confounders, 
availability of cause specific mortality, availability of 
falsification endpoints, and robustness of the findings 
across multiple sensitivity analyses provide evidence 
supporting the concept that patients with acute 
symptomatic pulmonary embolism admitted to high 
volume hospitals are more likely to survive than those 
admitted to low volume hospitals.
Meaning of the study
The relation between hospital volume of pulmonary 
embolism and outcome among patients with 
acute pulmonary embolism could have several 
explanations. Medical teams at low volume hospitals 
could be less experienced in providing care to 
patients with pulmonary embolism (including lack 
of timely recognition of clinical deterioration, lack 
of multidisciplinary efforts to stabilise the patients 
such as the use of pulmonary embolism response 
teams (PERTs), or lack of adherence to guidelines and 
available evidence for routine or advanced treatments), 
which could lead to worse outcomes in patients at such 
institutions. In fact, our study showed that clinicians 
at low volume hospitals adhered to evidence based 
guidelines less frequently, which has been shown to 
correlate with patient outcomes.21
Our findings have implications on how best to manage 
patients with acute symptomatic pulmonary embolism 
in the future. Educational strategies could be developed 
towards improving the knowledge and clinical expertise 
of physicians from low volume hospitals. Improved 
knowledge is particularly important because we observed 
evidence of both overtreatment and undertreatment 
with reperfusion treatments for pulmonary embolism 
in low volume hospitals (table S2). Thus, initiatives that 
could help improve the practitioners’ knowledge and 
adherence to guidelines recommendations at low volume 
hospitals, timely transfer of patients with pulmonary 
embolism (especially severe cases) to high volume 
hospitals, and dissemination of PERT teams across the 
hospitals (such as multidisciplinary teams caring for 
patients with ST elevation myocardial infarction) could 
be considered. Currently, little evidence exists on the 
benefits of PERT teams for improving patient outcomes, 
quality of life, and cost.22-25 Findings from our study 
would reinforce the interest in this area, which deserves 
focused investigations.
strengths and limitations of study
Our study had several potential limitations. Firstly, 
despite our best efforts, the possibility of residual 
confounding still remains. Nevertheless, we did adjust 
for age, sex, comorbidities, severity of pulmonary 
embolism, and laboratory results, and still found 
table 2 | Observed rates of mortality and non-fatal outcomes by hospital volume quarter (Q)
Overall/total no (%)  
of patients
Hospital volume
Q1 (<15 patients/year) Q2 (15-25 patients/year) Q3 (>25-40 patients/year) Q4 (>40 patients/year)
Mortality
30 day PE related mortality 201/8596 (2.3) 125/8130 (1.5) 148/9750 (1.5) 194/12 781 (1.5)
30 day all cause mortality 525/8596 (6.1) 433/8130 (5.3) 459/9750 (4.7) 722/12 781 (5.6)
7 day PE related mortality 153/8596 (1.8) 91/8130 (1.1) 110/9750 (1.1) 154/12 781 (1.2)
7 day all cause mortality 236/8596 (2.7) 169/8130 (2.1) 191/9750 (2.0) 291/12 781 (2.3)
non-fatal complications
30 day VTE recurrence 94/8596 (1.1) 69/8130 (0.8) 75/9750 (0.8) 125/12 781 (1.0)
30 day major bleeding 299/8596 (3.5) 270/8130 (3.3) 352/9750 (3.6) 496/12 781 (3.9)
PE=pulmonary embolism; VTE=venous thromboembolism.
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Fig 2 | relation between hospital volume and pulmonary embolism related mortality. 
Data are adjusted odds ratios (95% confidence intervals)
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a consistent relation between hospital volume and 
outcome. The severity of pulmonary embolism might 
have accounted for some of the differences between the 
groups’ outcomes. However, because patients admitted 
to higher volume hospitals had more signs of clinical 
severity, the study findings suggest that the design 
might have caused a bias against hospital volume. 
Furthermore, the results of sensitivity analyses and 
falsification hypothesis analyses made it less likely 
that our results were driven by unmeasured residual 
confounding, and provided evidence of the robustness 
of the findings. In addition, the single data point of 
initial blood pressure and heart rate used to define 
severity could have affected our analysis. However, 
based on current guidelines and the published 
literature, prognostication of pulmonary embolism 
is based on the findings at the time of pulmonary 
embolism diagnosis. 
Secondly, similar to most studies looking into 
an association between volume and outcomes, 
our analysis cannot determine the direction of the 
association (that is, causality).26 Although high 
volume hospitals had better adherence to guideline 
recommendations in our study, their good quality 
of care might have been a driver in attracting more 
patients with pulmonary embolism, thereby increasing 
their volume. Additional qualitative and mixed 
methods research is needed to further understand the 
reasons for better outcomes in high volume centres, 
and the major areas for improvement in low volume 
centres. Although this study was performed over a long 
period of time, we did not find significant interaction 
between the volume-mortality relation and year of 
pulmonary embolism diagnosis. Finally, because our 
study cohort probably included hospitals that were 
enthusiastic about evidence based management 
of pulmonary embolism, reductions in mortality 
associated with increases in the annual volume of 
patients treated could be more pronounced compared 
with other hospitals where vested teams of motivated 
physicians for pulmonary embolism management 
do not exist. However, the RIETE registry is the only 
large scale, multinational, observational study of the 
spectrum of patients diagnosed with a pulmonary 
embolism, with continuous recruitment of patients for 
more than 10 years, and offers a unique opportunity to 
look at a large number of patients in various treatment 
settings, countries, and continents over a long period 
of time.
conclusions and policy implications
We observed an inverse association between annual 
hospital volume of pulmonary embolism and outcomes 
among patients with acute symptomatic pulmonary 
table 4 | sensitivity analysis for rates of pulmonary embolism related mortality*
Model no of patients no of hospitals Odds ratio (95% ci)
Main model 39 257 353 0.56 (0.33 to 0.95)
Excluding outlier hospitals† 33 142 231 0.53 (0.28 to 0.97)
Excluding hospitals with annual volume <5 patients/year 36 585 256 0.57 (0.33 to 0.98)
Excluding hospitals with annual volume >80 patients/year 34 295 344 0.50 (0.28 to 0.91)
Excluding younger patients (age <50) 30 770 345 0.51 (0.30 to 0.87)
Excluding unstable patients (systolic blood pressure <90 mm Hg) 35 916 348 0.59 (0.35 to 1.03)
Excluding patients who received reperfusion treatments‡ 35 962 345 0.53 (0.30 to 0.91)
*Odds ratios and 95% confidence intervals compare the highest quarter of hospital volume (>40 patients/year) with the lowest quarter (<15 patients/
year). Models adjusted for age, sex, cancer, immobilisation, chronic lung disease, chronic heart disease, heart rate, systolic blood pressure, simplified 
pulmonary embolism severity index, creatinine levels, and haemoglobin levels at hospital admission. Confidence intervals take into account clustering 
according to centre.
†Outlier hospitals in terms of volume excluded (annual volumes <5 or >80 patients/year).
‡Including systemic thrombolysis, catheter directed treatment, or surgical embolectomy.
table 3 | adjusted rates of mortality and non-fatal outcomes by hospital volume quarter (Q)*
variable
Hospital volume
Q1 (<15 patients/year) Q2 (15-25 patients/year) Q3 (>25-40 patients/year) Q4 (>40 patients/year)
Odds ratio (95% CI)†
30 day PE related mortality 1.0 0.66 (0.43 to 1.01) 0.61 (0.38 to 0.99) 0.56 (0.33 to 0.95)
30 day all cause mortality 1.0 0.68 (0.48 to 0.97) 0.73 (0.19 to 1.10) 0.78 (0.50 to 1.22)
7 day PE related mortality 1.0 0.65 (0.41 to 1.02) 0.68 (0.42 to 1.11) 0.60 (0.35 to 1.03)
7 day all cause mortality 1.0 0.72 (0.48 to 1.07) 0.72 (0.46 to 1.12) 0.76 (0.47 to 1.24)
30 day non-fatal VTE recurrence 1.0 0.82 (0.54 to 1.23) 0.74 (0.48 to 1.14) 0.76 (0.49 to 1.19)
30 day non-fatal major bleeding 1.0 0.92 (0.70 to 1.20) 0.90 (0.66 to 1.22) 1.07 (0.77 to 1.47)
Adjusted risk (%; 95% CI)‡
30 day PE related mortality 2.3 (1.8 to 2.8) 1.5 (1.0 to 2.1) 1.4 (0.9 to 2.0) 1.3 (0.7 to 1.9)
30 day all cause mortality 6.4 (5.4 to 7.3) 4.7 (3.5 to 5.8) 4.9 (3.5 to 6.4) 5.2 (3.4 to 7.0)
7 day PE related mortality 1.7 (1.3 to 2.1) 1.1 (0.7 to 1.5) 1.2 (0.7 to 1.6) 1.0 (0.6 to 1.5)
7 day all cause mortality 2.7 (2.1 to 3.2) 2.0 (1.4 to 2.6) 2.0 (1.3 to 2.7) 2.1 (1.3 to 2.9)
30 day non-fatal VTE recurrence 1.1 (0.8 to 1.4) 0.9 (0.5 to 1.1) 0.8 (0.5 to 1.1) 0.8 (0.5 to 1.2)
30 day non-fatal major bleeding 3.6 (3.1 to 4.2) 3.2 (2.5 to 3.9) 3.8 (2.9 to 4.7) 3.9 (2.8 to 4.9)
PE=pulmonary embolism; VTE=venous thromboembolism.
*Adjusted for age, sex, cancer, immobilisation, chronic lung disease, chronic heart disease, heart rate, systolic blood pressure, simplified pulmonary embolism severity index, creatinine levels, 
and haemoglobin levels at hospital admission. Confidence intervals and P values take into account clustering according to centre.
†Event rates were compared across quarters of hospital volume according to adjusted odds ratios (with 95% confidence intervals); the lowest quarter served as the reference group.
‡Adjusted values were determined with the main model evaluating hospital volume categorised into quarters.
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embolism. Additional research is needed to investigate 
whether developing strategies to improve the clinical 
expertise of low volume clinicians, triage and transfer 
of select high risk patient subgroups, and use of PERTs 
might lead to better patient outcomes.
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